The tumor microenvironment (TME), which is mostly composed of tumor cells, immune cells,
signaling molecules, stromal tissue, and the vascular system, is an integrated system that is …

Immune checkpoint blockade (ICB) induces a remarkable and durable response in a subset
of cancer patients. However, most patients exhibit either primary or acquired resistance to …

Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct
transcriptional subtypes, but implementing subtyping in the clinic has remained challenging …

Summary Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …

Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer
(ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 …

Purpose: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP)
significantly improved overall survival (OS) versus EP alone in extensive-stage small cell …

PURPOSE The phase III SKYSCRAPER-02 study determined whether the benefits of
atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of …

Background Adjuvant therapy with durvalumab, with or without tremelimumab, may have
efficacy in patients with limited-stage small-cell lung cancer who do not have disease …

The combination therapy of platinum-based chemotherapy and PD-L1 inhibitors but not the
single anti-PD-L1 therapy has significantly improved the prognosis of patients with small-cell …

Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …